Featuring perspectives from Dr Julie M Vose. (Video Program)
TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
Presenting Faculty Member
Julie M Vose, MD, MBA
Neumann M and Mildred E Harris Professor
Chief, Division of Hematology/Oncology
Nebraska Medical Center
Omaha, Nebraska
Advisory Committee: AstraZeneca Pharmaceuticals LP, Verastem Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Epizyme, Janssen Biotech Inc, Kite Pharma Inc, Legend Biotech; Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Incyte Corporation, Kite Pharma Inc, Merck, Novartis, Seattle Genetics.
Project Steering Committee Members
Bruce D Cheson, MD
Lymphoma Consultant
North Bethesda, Maryland
Advisory Committee: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Dr Reddy’s Laboratories Ltd, Epizyme, Genentech, a member of the Roche Group, Gilead Sciences Inc, Karyopharm Therapeutics, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, SymBio Pharmaceuticals Limited, TG Therapeutics Inc; Consulting Agreements: Astellas, Karyopharm Therapeutics, MorphoSys, Parexel International Corporation, SymBio Pharmaceuticals Limited; Contracted Research: AbbVie Inc, Adaptive Biotechnologies, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, TG Therapeutics Inc, Trillium Therapeutics Inc.
Andrew M Evens, DO, MSc
Associate Director for Clinical Services
Rutgers Cancer Institute of New Jersey
Medical Director, Oncology Service Line
RWJBarnabas Health
Director, Lymphoma Program, Division of Blood Disorders
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
Advisory Committee: Bayer HealthCare Pharmaceuticals, Epizyme, Seattle Genetics, TG Therapeutics Inc, Verastem Inc; Consulting Agreements: American Society for Radiation Oncology, American Society of Hematology; Contracted Research: Leukemia & Lymphoma Society, National Cancer Institute, National Institutes of Health, ORIEN, Tesaro, A GSK Company.
Christopher R Flowers, MD, MS
Chair, Professor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas
Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, OptumRx Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Burroughs Wellcome Fund, Celgene Corporation, Eastern Cooperative Oncology group, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, National Cancer Institute, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Takeda Oncology, TG Therapeutics Inc, V Foundation for Cancer Research; Data and Safety Monitoring Board/Committee: Denovo Biopharma.
Ann S LaCasce, MD, MMSc
Program Director, Fellowship in Hematology/Oncology
Associate Professor of Medicine, Harvard Medical School
Institute Physician
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Advisory Committee: Humanigen Inc; Consulting Agreement: Seattle Genetics; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company; Institutional Research Funding: Celgene Corporation, Forty Seven Inc, Seattle Genetics.
John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
Weill Cornell Medicine
New York, New York
Consulting Agreements: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Karyopharm Therapeutics, Miltenyi Biotec, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Sutro Biopharma Inc; Contracted Research: Agios Pharmaceuticals Inc, Celgene Corporation; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company.
Andrew D Zelenetz, MD, PhD
Medical Director, Medical Informatics
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Gilead Sciences Inc, MorphoSys; Consulting Agreements: Adaptive Biotechnologies, Amgen Inc, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Novartis, Roche Laboratories Inc, Verastem Inc; Contracted Research: BeiGene, Gilead Sciences Inc, MEI Pharma, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: BeiGene.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AbbVie Inc, Gilead Sciences Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Seattle Genetics.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Release date: April 2020
Expiration date: April 2021
(WIFI is recommended for best performance):